Overview

Efgartigimod for the Treatment of Acute Optic Neuritis

Status:
NOT_YET_RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation). The main questions it aims to answer are: * Is it feasible to use efgartigimod alfa for optic neuritis? * Is it feasible to run a larger trial testing efgartigimod alfa in optic neuritis? * Does efgartigimod alfa work better than placebo in improving how quickly and how much vision returns? Participants will: * have their vision and blood tested * be asked questions about their vision * will receive standard of care treatment with steroids regardless of whether they are receiving efgartigimod alfa or not * will have periodic visits over 6 months
Phase:
PHASE2
Details
Lead Sponsor:
Anastasia Vishnevetsky, MD, MPH
Collaborator:
argenx
Treatments:
efgartigimod alfa